
Surabhi Dangi-Garimella, PhD
Articles by Surabhi Dangi-Garimella, PhD




A combined analysis of data gathered from the Canadian Health Measures Survey and the US–National Health and Nutrition Examination Survey found a 2.5% to 3.5% increase in the 10-year risk of cardiovascular disease in patients with a hepatitis C virus (HCV) infection.

The American Journal of Managed Care® sat down with Barbara McAneny, MD, president of the American Medical Association (AMA), to discuss how the AMA is working to "help create the healthcare system of the future."

A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

A kidney transplant patient treated with direct-acting antivirals (DAAs) for a chronic hepatitis C virus (HCV) infection showed reactivation of the hepatitis B virus (HBV), which proved fatal. The authors of the report recommend a call to action for including HBV testing as part of the patient’s work-up in transplant recipients who are on immunosuppressants, especially in the context of abnormal liver tests.

Ibrutinib combined with obinutuzumab had better progression-free survival (PFS) at 30 months than the standard chemoimmunotherapy regimen, chlorambucil plus obinutuzumab, regardless of high-risk genomic features in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who had never been treated.

While several associations between constitutional syndromes, such as Down syndrome, and predisposition to cancers have been recognized, recommendations for surveillance or clear association between the 2 are lacking.

According to the results of Alliance A041202, an international multicenter phase 3 trial, ibrutinib produces superior progression-free survival (PFS) compared with standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL) and adding rituximab does not improve the ibrutinib response.

Health resource utilization data gathered from the TRANSCEND-NHL trial have found that longer stays in the intensive care unit have a significant impact on the cost of care due to cytokine release syndrome (CRS) following treatment with chimeric antigen receptor (CAR) T cells.

Patients with sickle cell disease (SCD) typically face episodic emergency department (ED) and inpatient encounters, and innovative interventions are necessary to improve adherence to hydroxyurea treatment among youth suffering from SCD. These were the findings of 2 studies presented during an outcomes research session at the 60th American Society of Hematology Annual Meeting & Exposition.

A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found a similar response as well as toxicity compared with the ZUMA-1 clinical trial.

The Society of Obstetricians and Gynaecologists of Canada and the Canadian Society for Exercise Physiology have released consensus guidelines that will provide guidance for pregnant women as well as their clinical care providers on prenatal physical activity.

To better understand the characteristics of patients with chronic kidney disease who require hemodialysis or renal transplant, researchers in Brazil evaluated the prevalence of resistance-associated substitutions to direct-acting antivirals in this population who also carry the hepatitis C virus (HCV).

Rheumatoid arthritis and juvenile idiopathic arthritis increase the risk of preterm delivery (PTD) in pregnant women. Additionally, treatment with corticosteroid can lead to a 2- to 5-fold increased risk of PTD in both groups, independent of disease activity.

According to a new study presented at The Liver Meeting, combining universal screening for the hepatitis C virus (HCV) with reflex RNA PCR in pregnant women is more cost-effective than risk-based screening.

Research presented at The Liver Meeting, held by the American Association for the Study of Liver Diseases, found high rates of adherence, treatment completion, and sustained virologic response among patients infected with the hepatitis C virus (HCV) who inject drugs. These findings led authors to recommend inclusion of this subset of patients in HCV treatment programs.

Systemic lupus erythematosus, characterized by systemic inflammation in multiple organs, has a higher probability of being diagnosed in women who experienced emotional or physical abuse when growing up, according to a study presented at the 2018 American College of Rheumatology (ACR)/The Association of Rheumatology Health Professionals Annual Meeting.

According to a review published in Cancer Management and Research, biosimilar products present a viable cost-saving tool for providers participating in value-based care programs such as the Medicare Shared Savings Program or the Oncology Care Model.

A review published in the International Journal of Molecular Sciences highlights existing knowledge gaps in understanding the safety and impact of tumor necrosis factor (TNF) α inhibitors in pregnant women suffering from inflammatory conditions such as psoriasis and rhaumatoid arthritis.

To speak about the success and continued development of Priority Health's payment reform model in cancer care, John Fox, MD, medical director at Priority Health, joined Dennis Zoet, chief business development officer at Cancer and Hematology Centers of Western Michigan, on a panel at the Community Oncology Alliance Payer Exchange Summit.

New research presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting, in Chicago, Illinois, reported on progress over the past 20 years in the care of pregnant women with systemic lupus erythepatosus (SLE) that has led to a decline in maternal mortality and intrauterine fetal death among patients with SLE.

At the Community Oncology Alliance Payer Exchange Summit, healthcare policy experts from a government relations firm and from the pharmaceutical industry provided an update on the progress with value-based agreements and also discussed the challenges posed by the existing infrastructure and operational framework.

The Community Oncology Alliance (COA) has been working with its member practices and some payer partners who have successfully implemented innovative care delivery and payment models to develop a 2.0 version of CMS’ Oncology Care Model (OCM). A progress report was presented at COA’s Payer Exchange Summit held October 29-30 in Tyson’s Corner, Virginia.

While practice transformation is vital, community-based clinics continue to struggle with emergency department (ED) use, hospitalization, and risk stratification as they identify ways to reduce unnecessary expenditures within their Oncology Care Model (OCM) practice.

The field of patient-reported outcomes (PROs) has witnessed a slow and steady progress over the past few years. Here are a few recent developments with utilizing and measuring PROs.

Amgen has announced that the price of its proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, evolocumab (Repatha), will be reduced by 60%, from an annual price of $14,100 down to $5850.

At the National Association of ACOs Fall 2018 conference, private payers discussed how they are working with accountable care organizations (ACOs) to create new opportunities in the commercial market.

Two posters presented at the North American Neuroendocrine Tumor Society (NANETS) annual meeting, October 4-6 in Seattle, Washington, lend support to the idea of targeted treatment for neuroendocrine tumors.
Latest Updated Articles
- The Implications of Halting Biologics in RA Patients in Remission
Published: October 21st 2014 | Updated:
- CDC Recommends a Prophylactic Pill for HIV
Published: October 21st 2014 | Updated:
- The Elusive HCV Seeks Mitochondrial Help
Published: October 23rd 2014 | Updated:
- Ebola: Diagnosis, Prevention, and Treatment
Published: October 23rd 2014 | Updated:
- Merck's Rapid Strides With Pembrolizumab
Published: October 27th 2014 | Updated:
- ASCO Members Take a Stand on Access to Care for Low-Income Individuals
Published: November 18th 2014 | Updated: